American Society of Hirudotherapy

Rapid molecular species identification of mammalian scat samples using nanopore adaptive sampling

Methodology study published in Journal of Mammalogy (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomics & ProteomicsFrank LE et al. · Journal of mammalogy, 2024

Abstract

Accurate taxonomic species identification is essential to the study of mammals. Despite this necessity, rapid and accurate identification of cryptic, understudied, and elusive mammals remains challenging. Traditional barcoding of mitochondrial genes is standard for molecular identification but requires time-consuming wet-lab methodologies. Recent bioinformatic advancements for nanopore sequencing data offer exciting opportunities for noninvasive and field-based identification of mammals. Nanopore adaptive sampling (NAS), a polymerase chain reaction (PCR)-free method, selectively sequences regions of DNA according to user-specified reference databases. Here, we utilized NAS to enrich mammalian mitochondrial genome sequencing to identify species. Fecal DNA extractions were sequenced from 9 mammals, several collected in collaboration with Minnesota Tribal Nations, to demonstrate utility for NAS barcoding of noninvasive samples. By mapping to the entire National Center for Biotechnology Information mammalian mitochondrial reference genome database and bioinformatically analyzing highly similar matches, we successfully produced species identifications for all fecal samples. Eight of 9 species identifications matched previous PCR or animal/fecal appearance-based identifications. For the ninth species, our genetic data indicate a misidentification stemming from the original study. Our approach has a range of applications-particularly in field-based wildlife research, conservation, disease surveillance, and monitoring of wildlife trade. Of importance to Minnesota tribes is invasive species monitoring, detections, and confirmation as climate impacts cause changes in biodiversity and shifts in species distributions. The rapid assessment techniques described here will be useful as new introductions and range expansions of native and invasive species may first be detected by the presence of signs such as scat rather than direct observations and will be helpful for chronically understaffed tribal natural resources agencies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Develops Oxford Nanopore adaptive sampling protocol for rapid species identification from scat samples — technology directly transferable to leech identification pipelines.

Why This Matters for Hirudotherapy

This study developed a PCR-free nanopore adaptive sampling approach to rapidly identify mammalian species from fecal DNA by selectively sequencing mitochondrial genomes against reference databases, successfully producing species-level identifications for all 9 samples tested. The method has applications in field-based wildlife research, conservation, invasive species monitoring, and disease surveillance. This article has no connection whatsoever to hirudotherapy, leech biology, the leech secretome, or any topic relevant to ASH's domain. The study is entirely focused on molecular taxonomy and bioinformatic methodology for mammalian identification using scat samples. There is no defensible leech-related relevance to justify inclusion in the ASH research library.

Citation

Rapid molecular species identification of mammalian scat samples using nanopore adaptive sampling.

Frank LE et al. · Journal of mammalogy, 2024

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.